

Page Denied

STAT




NATIONAL DRUG POLICY BOARD

Washington, D.C. 20530

15396X

APR 28 1988

Coll. G-SR



STAT

Mr. David Pickens
Executive Director
National Drug Policy Board
9th & Pennsylvania Ave., N.W.
Washington, D.C. 20530

Dear Mr. Pickens:

As requested in your April 4 memorandum, enclosed are comments on the first draft of the 1987 Progress Report.

Annotations have been made directly on Chapters II and VII of the draft report. Additional material has been received from INTERPOL for Chapter VII. In addition, I strongly recommend that Chapter I be discarded in favor of either an executive summary or a lead-in with Chapter II.

Should you have any questions regarding the report, please contact Mr. Thomas Byrne, NDIC Working Group Chairman, on 633-1071, for further information.

Sincerely,

John C. Lawn, Chairman
National Drug Intelligence
Committee

Enclosure

cc: NDIC Members
Tom Byrne/OI



NATIONAL DRUG POLICY BOARD

Washington, D.C. 20530

MAY 4 1988

Honorable Francis A. Keating II
Assistant Secretary (Enforcement)
Department of the Treasury
15th & Pennsylvania Avenue, N.W.
Washington, D.C. 20220

Dear Mr. Keating:

I have received your April 5 request to review the Omnibus Anti-Drug Abuse Act of 1988 to determine if its provisions would significantly affect the National Drug Intelligence Strategy and Implementation Plan. From an analysis of S 2205 it would appear that nothing in the proposed bill would contravene our drug intelligence strategy. Nevertheless, the bill is not adequate to our national drug intelligence needs and could affect the strategy in several ways.

If the bill is passed and fully funded there will be additional resources for EPIC (\$4 million). In addition, agencies receiving additional positions may allocate some of them to their intelligence programs. But, the omnibus bill fails to authorize directly additional resources for drug intelligence programs.

Other provisions of the bill, such as the Latin American Anti-Drug Strike Force and the Southwest Border Task Force would create a greater demand for drug intelligence information and services. Neither the law enforcement agencies nor the Intelligence Community have been authorized intelligence resources to address these new programs. Although not bearing on the strategy directly, certain provisions of the bill would realign strategic intelligence responsibilities among the drug control agencies. Thus, transferring from the Department of State to DEA the responsibilities to determine illicit drug crop acreages


~~LIMITED OFFICIAL USE~~

- 2 -

under cultivation and to assess the effectiveness of eradication programs would result in a disruption that may not be justifiable. It should also be noted that the increased pressure put on the validity of our strategic assessments will require greatly improved data collection and analysis. Here we depend a great deal on the Intelligence Community, and they have not been earmarked additional resources in this bill.

Because of the failure of the bill to provide additional resources for drug intelligence programs, the bill generally will strain our ability to implement the National Drug Intelligence Strategy. At this time, the National Drug Intelligence Committee has no legislative proposals for inclusion in an omnibus bill.

If I can be of any further assistance, please let me know.

Sincerely,


John C. Lawn
Chairman, National Drug
Intelligence Committee

cc: NDIC Members
Mr. David Pickens

LIMITED OFFICIAL USE